BeamCR, KaneshiroC, JangJY, et al.Differences between women and men in incidence rates of dementia and Alzheimer's disease. J Alzheimers Dis, 2018; 64(4):1077–1083; doi: 10.3233/jad-180141
2.
NiuH, Álvarez-ÁlvarezI, Guillén-GrimaF, et al.Prevalence and incidence of Alzheimer's disease in Europe: A meta-analysis [Prevalencia e incidencia de la enfermedad de Alzheimer en Europa: metaanálisis]. Neurologia Oct, 2017; 32(8):523–532; doi: 10.1016/j.nrl.2016.02.016
3.
FordND, CoxS, KoJY, et al.Hypertensive disorders in pregnancy and mortality at delivery hospitalization—United States, 2017–2019. MMWR Morb Mortal Wkly Rep, 2022; 71(17):585–591; doi: 10.15585/mmwr.mm7117a1
4.
GarovicVD, WhiteWM, VaughanL, et al.Incidence and long-term outcomes of hypertensive disorders of pregnancy. J Am Coll Cardiol, 2020; 75(18):2323–2334; doi: 10.1016/j.jacc.2020.03.028
5.
SchliepKC, McLeanH, YanB, et al.Association between hypertensive disorders of pregnancy and dementia: A systematic review and meta-analysis. Hypertension, 2023; 80(2):257–267; doi: 10.1161/hypertensionaha.122.19399
6.
AdankMC, HussainaliRF, OosterveerLC, et al.Hypertensive disorders of pregnancy and cognitive impairment: A prospective cohort study. Neurology, 2021; 96(5):e709–e718; doi: 10.1212/wnl.0000000000011363
7.
MielkeMM, MilicNM, WeissgerberTL, et al.Impaired cognition and brain atrophy decades after hypertensive pregnancy disorders. Circ Cardiovasc Qual Outcomes, 2016; 9(2 Suppl 1):S70–S76; doi: 10.1161/circoutcomes.115.002461
8.
RobertsRO, GedaYE, KnopmanDS, et al.The Mayo Clinic study of aging: Design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology, 2008; 30(1):58–69; doi: 10.1159/000115751
9.
MilicNM, CodsiE, Butler TobahYS, et al.Electronic algorithm is superior to hospital discharge codes for diagnoses of hypertensive disorders of pregnancy in historical cohorts. Mayo Clin Proc, 2018; 93(12):1707–1719; doi: 10.1016/j.mayocp.2018.08.031
10.
DavisSR, Castelo-BrancoC, ChedrauiP, et al.Understanding weight gain at menopause. Climacteric, 2012; 15(5):419–429; doi: 10.3109/13697137.2012.707385
11.
SzmuilowiczED, StuenkelCA, SeelyEW. Influence of menopause on diabetes and diabetes risk. Nat Rev Endocrinol, 2009; 5(10):553–558; doi: 10.1038/nrendo.2009.166
12.
GupteAA, PownallHJ, HamiltonDJ. Estrogen: An emerging regulator of insulin action and mitochondrial function. J Diabetes Res, 2015; 2015:916585; doi: 10.1155/2015/916585
13.
HarmanSM, BrintonEA, CedarsM, et al.KEEPS: The Kronos early estrogen prevention study. Climacteric, 2005; 8(1):3–12; doi: 10.1080/13697130500042417
14.
WhartonW, GleasonCE, DowlingNM, et al.The KEEPS-cognitive and affective study: Baseline associations between vascular risk factors and cognition. J Alzheimer's Dis, 2014; 40:331–341.
15.
EppersonCN, SammelMD, FreemanEW. Menopause effects on verbal memory: Findings from a longitudinal community cohort. J Clin Endocrinol Metab, 2013; 98(9):3829–3838; doi: 10.1210/jc.2013-1808
16.
GreendaleGA, KarlamanglaAS, MakiPM. The menopause transition and cognition. JAMA, 2020; 323(15):1495–1496; doi: 10.1001/jama.2020.1757
17.
MosconiL, BertiV, DykeJ, et al.Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition. Sci Rep, 2021; 11(1):10867; doi: 10.1038/s41598-021-90084-y
18.
DebetteS, MarkusHS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: Systematic review and meta-analysis. BMJ, 2010; 341:c3666; doi: 10.1136/bmj.c3666
RettbergJR, YaoJ, BrintonRD. Estrogen: A master regulator of bioenergetic systems in the brain and body. Front Neuroendocrinol, 2014; 35(1):8–30; doi: 10.1016/j.yfrne.2013.08.001
21.
PontifexM, VauzourD, MinihaneAM. The effect of APOE genotype on Alzheimer's disease risk is influenced by sex and docosahexaenoic acid status. Neurobiol Aging, 2018; 69:209–220; doi: 10.1016/j.neurobiolaging.2018.05.017
22.
ShumakerSA, LegaultC, RappSR, et al.Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The women's health initiative memory study: A randomized controlled trial. JAMA, 2003; 289(20):2651–2662; doi: 10.1001/jama.289.20.2651
23.
GleasonCE, DowlingNM, WhartonW, et al.Effects of hormone therapy on cognition and mood in recently postmenopausal women: Findings from the randomized, controlled KEEPS-cognitive and affective study. PLoS Med, 2015; 12(6):e1001833; discussion e1001833; doi: 10.1371/journal.pmed.1001833
24.
EspelandMA, ShumakerSA, LengI, et al.Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med, 2013; 173(15):1429–1436; doi: 10.1001/jamainternmed.2013.7727
25.
HendersonVW, St JohnJA, HodisHN, et al.Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis. Neurology, 2016; 87(7):699–708; doi: 10.1212/wnl.0000000000002980
26.
The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022; 29(7):767–794; doi: 10.1097/gme.0000000000002028
